Key result
Multimodal baseline model predicts subclinical myocardial dysfunction with ~0.80 AUC.
Why the study?
Anthracycline cardiotoxicity is often silent at the subclinical stage, and current measures like LVEF detect injury late while GLS is usually used alone.
Does a baseline model integrating 2D speckle-tracking GLS, conventional echocardiographic parameters, and clinical factors accurately predict subclinical myocardial dysfunction in breast cancer patients receiving doxorubicin-based chemotherapy?
Cohort (n=200)
No
Does a baseline model integrating 2D speckle-tracking GLS, conventional echocardiographic parameters, and clinical factors accurately predict subclinical myocardial dysfunction in breast cancer patients receiving doxorubicin-based chemotherapy?
Effect estimate: AUC 0.803
A multiparametric baseline prediction model combining GLS, conventional echocardiography, and clinical factors provides strong discrimination for identifying breast cancer patients at high risk of early subclinical doxorubicin-induced myocardial dysfunction.
BACKGROUND: Anthracycline cardiotoxicity is often silent at the subclinical stage. Left ventricular ejection fraction (LVEF) detects injury late, and global longitudinal strain (GLS) is sensitive but usually used alone. This study aimed to develop and internally validate a baseline model combining speckle-tracking GLS, conventional echocardiography, and clinical factors to identify women at high risk of subclinical myocardial dysfunction before doxorubicin (DOX) chemotherapy. METHODS: In a single-center prospective study, 200 breast cancer patients scheduled for DOX-based chemotherapy underwent baseline and 1-month assessment. The primary outcome was subclinical myocardial dysfunction, defined as > 15% relative GLS reduction with preserved LVEF. P < 0.10 variables in univariable analysis entered multivariable logistic regression for nomogram construction. Discrimination, calibration, and decision curve analysis used 1000-bootstrap validation. RESULTS: Subclinical myocardial dysfunction occurred in 60 of 200 patients (30.0%). Independent predictors were baseline GLS, LDL-C, trastuzumab use, planned cumulative dose, LAVI, and hypertension. The model reached an AUC of 0.803, higher than baseline GLS, a clinical-only model, and baseline LVEF. The bootstrap-corrected C-index was 0.777. CONCLUSION: A baseline nomogram combining GLS, conventional echocardiography, and clinical factors may help identify patients at high risk of early subclinical myocardial dysfunction before chemotherapy, outperforming single parameters and supporting risk-stratified monitoring.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Breast cancer (n=200). Predictive model combining GLS, conventional echocardiography, and clinical factors vs. Baseline GLS, clinical-only model, and baseline LVEF was evaluated on Subclinical myocardial dysfunction, defined as > 15% relative GLS reduction with preserved LVEF (AUC 0.803). A baseline predictive model combining speckle-tracking GLS, conventional echocardiography, and clinical factors identified patients at high risk of subclinical myocardial dysfunction with an AUC of 0.803.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: